共 19 条
- [1] Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (05) : 523 - 525Shah, Syed RazaAli, ArrojIkram, Sohail
- [2] Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial[J]. CIRCULATION, 2019, 140Szarek, MichaelSteg, Philippe G.DiCenso, DinaBhatt, Deepak L.Bittner, Vera A.Budaj, AndrzejDiaz, RafaelGoodman, Shaun G.Gotcheva, NinaJukema, J. WouterPordy, RobertRoe, Matthew T.Sourdille, TimotheeWhite, Harvey D.Xavier, DenisZeiher, Andreas M.Schwartz, Gregory G.
- [3] Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial[J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (11):Szarek, MichaelSteg, Ph. GabrielDiCenso, DinaBhatt, Deepak L.Bittner, Vera A.Budaj, AndrzejDiaz, RafaelGoodman, Shaun G.Gotcheva, NinaJukema, J. WouterPordy, RobertRoe, Matthew T.Sourdille, TimotheeWhite, Harvey D.Xavier, DenisZeiher, Andreas M.Schwartz, Gregory G.Steg, Ph. GabrielBhatt, Deepak L.Bittner, Vera A.Diaz, RafaelGoodman, Shaun G.Harrington, Robert A.Jukema, J. WouterSzarek, MichaelZeiher, Andreas M.Tricoci, PierluigiRoe, Matthew T.Mahaffey, Kenneth W.Edelberg, Jay M.Hanotin, CorinneLecorps, GuillaumeMoryusef, AngelePordy, RobertSasiela, William J.Tamby, Jean-FrancoisAylward, Philip E.Drexel, HeinzSinnaeve, PeterDilic, MirzaGotcheva, Nina N.Goodman, Shaun G.Prieto, Juan-CarlosYong, HuoLopez-Jaramillo, PatricioPecin, IvanReiner, ZeljkoOstadal, PetrPoulsen, Steen HvitfeldtViigimaa, Margus
- [4] Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry[J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 343 - 352Becher, Peter MoritzSavarese, GianluigiBenson, LinaDahlstrom, UlfKarlstrom, PatricMol, Peter G. M.Metra, MarcoBhatt, Deepak L.Pitt, BertramLund, Lars H.
- [5] Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 194 - 195Becher, P. M. Peter MoritzSavarese, G. S.Benson, L.Dahlstrom, U.Bhatt, D. L.Pitt, B.Lund, L. H.
- [6] The Effect of the Dual SGLT1 and 2 Inhibitor Sotagliflozin on Cardiovascular Mortality and Hospital Readmission Rates for Heart Failure at 30 and 90 Days Post Discharge in Patients With Type 2 Diabetes Hospitalized for Worsening Heart Failure in the SOLOIST-WHF Trial[J]. CIRCULATION, 2022, 146Pitt, BertramBhatt, Deepak L.Szarek, MichaelSun, FranklinDavies, Michael J.Steg, Philippe G.
- [7] Seeking patient-centered trial outcomes: The case for days alive out of hospital[J]. AMERICAN HEART JOURNAL, 2022, 248 : 172 - 174Faggioni, MichelaFanaroff, Alexander C.
- [8] Seeking patient-centered trial outcomes: The case for days alive out of hospital[J]. AMERICAN HEART JOURNAL, 2022, 248 : 172 - 174Faggioni, MichelaFanaroff, Alexander C.
- [9] DAYS ALIVE OUT OF HOSPITAL WITH INITIAL INVASIVE VS CONSERVATIVE MANAGEMENT IN THE ISCHEMIA TRIAL[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3 - 3White, HarveyO'Brien, SeanAlexander, KarenBangalore, SripalLi, Jiang HaoManjunath, CholenahallyLopez-Sendon, JosePeteiro, JesusGosselin, GilbertBerger, JeffreyMaggioni, Aldo PietroBoden, WilliamReynolds, HarmonyHochman, JudithMaron, David
- [10] Novel Palliative Care Integration Program increases Days Alive and Out of Hospital and Reduces Inpatient Direct Costs Among Left Ventricular Assist Device Patients[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S173 - S173Nakagawa, S.Luna, J. M.Topkara, V. K.Yuzefpolskaya, M.Vawdrey, D.Garan, A. R.Takayama, H.Takeda, K.Colombo, P. C.Naka, Y.Blinderman, C. D.